CGTX
What one share of Cognition Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina.
Cognition Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.19 |
|---|---|
| Cash and investments | $0.36 |
| Book value | $0.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$23.76 | $0.02 | −$6.78 | — | −$126.55 |
| 2021 | — | −$3.13 | $0.01 | −$0.70 | — | — |
| 2022 | — | −$0.91 | $0.01 | −$0.79 | — | $1.39 |
| 2023 | — | −$0.86 | $0.00 | −$0.54 | — | $0.76 |
| 2024 | — | −$0.85 | $0.00 | −$0.72 | — | $0.31 |
| 2025 | — | −$0.32 | — | −$0.34 | — | $0.39 |